Robert Launois
Research Subjects
Robert Launois has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
K Le Lay
12 shared publicationsL Riou França
8 shared publicationsF Maunoury
4 shared publicationsN Chemali
4 shared publicationsS Avoinet
4 shared publicationsS Payet
4 shared publications
Latest Publications
- 1 April 2022
- Published by Elsevier in Value in Health
- Vol. 25 (4) , 571-581
Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL Study
- 1 April 2022
- Published by Elsevier in Value in Health
- Vol. 25 (4) , 571-581
Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL Study
- 18 June 2021
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 80 (2) , 131-144
Évaluer autrement les parcours de soins coordonnés article 51 LFSS 2018 : une innovation, les protocoles réalistes
- 18 June 2021
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 80 (2) , 131-144
Évaluer autrement les parcours de soins coordonnés article 51 LFSS 2018 : une innovation, les protocoles réalistes
- 19 March 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (10) , 1921-1927
Importance of out‐of‐pocket costs for adult patients with atopic dermatitis in France
Background: Currently, few studies investigated the economic burden of atopic dermatitis (AD) in adult patients and specifically the estimation of out‐of‐pocket costs. Patients with skin disorders primarily use comfort care to ease dryness, itch or pain, and the costs of comfort care are not subject to any reimbursement from mandatory or complementary insurance.Objective: The purpose of this study was to measure the medical and non‐medical expenses paid by the patient.Methods: Eczema Cohort Longitudinal Adults was a non‐interventional study that aimed to assess the burden of AD in terms of quality of life and financial consequences. A self‐assessment questionnaire was distributed to adult patients who were cared in four French hospitals. Patients were asked to list the resources consumed for the treatment of AD during the last 12 months and to estimate the corresponding amount of money they had to pay out of their own pockets. The severity of AD was subjected to a stratification based on the PO‐SCORAD score.Results: A total of 1024 patients answered the questionnaire: 31.9% with severe AD, 40.4% with moderate AD and 27.6% with mild AD. The mean annual out‐of‐pocket cost was €462.1 for severe AD and €247.4 for moderate AD. Emollients were the most commonly used product: 74.4% for an average out‐of‐pocket cost of €151.4. The out‐of‐pocket costs increased significantly with the severity: 27% of patients with severe AD declared having bought specially textured clothes, while 19% of patients with moderate AD reported the same. The corresponding mean out‐of‐pocket costs were €162 and €91, respectively.Conclusion: The amount of out‐of‐pocket costs for patients with AD for essential medical and non‐medical expenses is relatively high, compared to the average out‐of‐pocket cost for French households. Integration of these essential resources into the list of reimbursed products and services appears necessary for a better coverage of AD.
- 19 March 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (10) , 1921-1927
Importance of out‐of‐pocket costs for adult patients with atopic dermatitis in France
Background: Currently, few studies investigated the economic burden of atopic dermatitis (AD) in adult patients and specifically the estimation of out‐of‐pocket costs. Patients with skin disorders primarily use comfort care to ease dryness, itch or pain, and the costs of comfort care are not subject to any reimbursement from mandatory or complementary insurance.Objective: The purpose of this study was to measure the medical and non‐medical expenses paid by the patient.Methods: Eczema Cohort Longitudinal Adults was a non‐interventional study that aimed to assess the burden of AD in terms of quality of life and financial consequences. A self‐assessment questionnaire was distributed to adult patients who were cared in four French hospitals. Patients were asked to list the resources consumed for the treatment of AD during the last 12 months and to estimate the corresponding amount of money they had to pay out of their own pockets. The severity of AD was subjected to a stratification based on the PO‐SCORAD score.Results: A total of 1024 patients answered the questionnaire: 31.9% with severe AD, 40.4% with moderate AD and 27.6% with mild AD. The mean annual out‐of‐pocket cost was €462.1 for severe AD and €247.4 for moderate AD. Emollients were the most commonly used product: 74.4% for an average out‐of‐pocket cost of €151.4. The out‐of‐pocket costs increased significantly with the severity: 27% of patients with severe AD declared having bought specially textured clothes, while 19% of patients with moderate AD reported the same. The corresponding mean out‐of‐pocket costs were €162 and €91, respectively.Conclusion: The amount of out‐of‐pocket costs for patients with AD for essential medical and non‐medical expenses is relatively high, compared to the average out‐of‐pocket cost for French households. Integration of these essential resources into the list of reimbursed products and services appears necessary for a better coverage of AD.
- 1 November 2018
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 76 (6) , 421-435
Comment mesurer l’efficacité en vie réelle ?
- 1 November 2018
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 76 (6) , 421-435
Comment mesurer l’efficacité en vie réelle ?
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A584-A585
Economic Evaluation Of Cerebral Oximetry Monitoring In Carotid Endarterectomy: The Emocar Randomized Controlled Trial (May 2011 - April 2016)
- 1 October 2017
- Published by Elsevier in Value in Health
- Vol. 20 (9) , A584-A585
Economic Evaluation Of Cerebral Oximetry Monitoring In Carotid Endarterectomy: The Emocar Randomized Controlled Trial (May 2011 - April 2016)
- Open Access
- 22 May 2016
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 9 (4) , 473-482
Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France
Background: Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome that occurs most often in a context of acute or chronic liver disease. Despite the seriousness of the pathology, only a few treatments have been developed for improving its management. Rifaximin-α is the first treatment that has been clinically developed for overt HE (OHE) episodes. Recent results of clinical studies demonstrated its significant improvement in the health-related quality of life. The objective of the current study was to estimate the long-term cost-effectiveness of rifaximin-α used in combination with lactulose compared with lactulose monotherapy in cirrhotic patients, who have experienced at least two prior OHE events. Methods: A Markov model was used to estimate rifaximin-α cost-effectiveness, evaluating it from the perspective of all contributors as recommended by French health technology assessment guidelines. Costs were based on current French treatment practices. The transition between health states was based on the reanalysis of the rifaximin-α pivotal clinical trials RFHE3001 and RFHE3002. The main outcome of the model was cost per quality adjusted life year (QALY). Results: The results indicate that rifaximin-α is a cost-effective treatment option with an incremental cost per QALY gained of €19,187 and €18,517 over two different time horizons (2 and 5 years). The robustness of the model was studied using probabilistic sensitivity analysis. Conclusion: For the societal willingness to pay threshold of €27,000 per QALY gained, rifaximin-α in combination with lactulose is a cost-effective and affordable treatment for patients who have experienced at least two prior overt HE episodes.
- 22 May 2016
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 9 (4) , 473-482
Open AccessCost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France
Background: Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome that occurs most often in a context of acute or chronic liver disease. Despite the seriousness of the pathology, only a few treatments have been developed for improving its management. Rifaximin-α is the first treatment that has been clinically developed for overt HE (OHE) episodes. Recent results of clinical studies demonstrated its significant improvement in the health-related quality of life. The objective of the current study was to estimate the long-term cost-effectiveness of rifaximin-α used in combination with lactulose compared with lactulose monotherapy in cirrhotic patients, who have experienced at least two prior OHE events. Methods: A Markov model was used to estimate rifaximin-α cost-effectiveness, evaluating it from the perspective of all contributors as recommended by French health technology assessment guidelines. Costs were based on current French treatment practices. The transition between health states was based on the reanalysis of the rifaximin-α pivotal clinical trials RFHE3001 and RFHE3002. The main outcome of the model was cost per quality adjusted life year (QALY). Results: The results indicate that rifaximin-α is a cost-effective treatment option with an incremental cost per QALY gained of €19,187 and €18,517 over two different time horizons (2 and 5 years). The robustness of the model was studied using probabilistic sensitivity analysis. Conclusion: For the societal willingness to pay threshold of €27,000 per QALY gained, rifaximin-α in combination with lactulose is a cost-effective and affordable treatment for patients who have experienced at least two prior overt HE episodes.
- 1 February 2016
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 51 (2) , 268-274
Psychometric Validation of the 14 items ChronIc Venous Insufficiency Quality of Life Questionnaire (CIVIQ-14): Confirmatory Factor Analysis
- 1 February 2016
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 51 (2) , 268-274
Psychometric Validation of the 14 items ChronIc Venous Insufficiency Quality of Life Questionnaire (CIVIQ-14): Confirmatory Factor Analysis
- 1 April 2015
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 3 (2) , 219-227.e3
Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs
- 1 April 2015
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 3 (2) , 219-227.e3
Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs
- Open Access
- 1 December 2014
- Published by CAIRN.INFO in Revue française des affaires sociales
- No. 4,p. 156-178
Paiement à la performance et fixation conditionnelle du prix du médicament
L’effet d’un médicament peut être différent en pratique quotidienne de ce qu’il était au cours de la recherche clinique ou au moment de la négociation de son prix avant sa mise sur le marché des médicaments remboursables. Les contrats conditionnels, fondés sur les résultats de santé, ont été créés pour se prémunir contre ce risque. Moyennant un accord rapide sur le prix, le laboratoire pharmaceutique prend l’engagement de rembourser en partie ou en totalité la valeur qui a été négociée si les résultats du traitement ne sont pas à la hauteur des espoirs suscités. Ces contrats d’accès au marché des médicaments remboursables sont étudiés ici à la lumière des schémas d’études qui président à leur mise en œuvre. Ils reposent pour l’essentiel sur des études descriptives ou normatives sans groupe témoin, études qui ne permettent pas de mesurer l’impact du médicament sur la santé. La fixation du prix du médicament sur de telles bases risque d’être fragilisée par la modeste qualité des preuves avancées pour en justifier l’octroi. Pour remédier à cette situation, nous proposons la mise en place d’études observationnelles comparatives, dont les populations devront être rendues comparables par la mise en œuvre des techniques micro-économétriques appropriées.
- 1 December 2014
- Published by CAIRN.INFO in Revue française des affaires sociales
- No. 4,p. 156-178
Open AccessPaiement à la performance et fixation conditionnelle du prix du médicament
L’effet d’un médicament peut être différent en pratique quotidienne de ce qu’il était au cours de la recherche clinique ou au moment de la négociation de son prix avant sa mise sur le marché des médicaments remboursables. Les contrats conditionnels, fondés sur les résultats de santé, ont été créés pour se prémunir contre ce risque. Moyennant un accord rapide sur le prix, le laboratoire pharmaceutique prend l’engagement de rembourser en partie ou en totalité la valeur qui a été négociée si les résultats du traitement ne sont pas à la hauteur des espoirs suscités. Ces contrats d’accès au marché des médicaments remboursables sont étudiés ici à la lumière des schémas d’études qui président à leur mise en œuvre. Ils reposent pour l’essentiel sur des études descriptives ou normatives sans groupe témoin, études qui ne permettent pas de mesurer l’impact du médicament sur la santé. La fixation du prix du médicament sur de telles bases risque d’être fragilisée par la modeste qualité des preuves avancées pour en justifier l’octroi. Pour remédier à cette situation, nous proposons la mise en place d’études observationnelles comparatives, dont les populations devront être rendues comparables par la mise en œuvre des techniques micro-économétriques appropriées.
- Open Access
- 29 January 2014
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 2 (1)
Health economic value of an innovation: delimiting the scope and framework of future market entry agreements
Background and objectives: The objective of our paper is to offer a new, payer-friendly taxonomy of market entry agreements (MEAs) that aims to twin contracts with their methodological designs in an effort to clarify the distinction between contracts that are based on performance and those that are based on demonstrated effect. Methods: Our analysis proceeds in two stages: First, we delimit the scope and framework of pay for performance (P4P) and pay for demonstrated effect (P4E) agreements. Second, we distinguish the methodological designs supporting the implementation of each of these contracts. Results: We elucidate why P4P contracts prevent the payer from funding the true effectiveness of an innovation by expanding on their limitations. These include: 1) the normative nature of comparisons, 2) the impossibility of true effect imputability for each individual, and 3) the use of intermediary outcome measures. We then explore three main criticisms that payers must take into account when reasoning in terms of performance rather than in terms of the product effectiveness. Conclusion: The potential effect that performance-based reimbursements may have on dissociating the components of the cost-effectiveness ratio constitutes an obstacle to a true health economic reasoning. Keywords: risk sharing; pay for performance contract; comparative effectiveness research; cost-effectiveness studies (Published: 23 June 2014) Citation: Journal of Market Access & Health Policy 2014, 2: 24988 - http://dx.doi.org/10.3402/jmahp.v2.24988
- 29 January 2014
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 2 (1)
Open AccessHealth economic value of an innovation: delimiting the scope and framework of future market entry agreements
Background and objectives: The objective of our paper is to offer a new, payer-friendly taxonomy of market entry agreements (MEAs) that aims to twin contracts with their methodological designs in an effort to clarify the distinction between contracts that are based on performance and those that are based on demonstrated effect. Methods: Our analysis proceeds in two stages: First, we delimit the scope and framework of pay for performance (P4P) and pay for demonstrated effect (P4E) agreements. Second, we distinguish the methodological designs supporting the implementation of each of these contracts. Results: We elucidate why P4P contracts prevent the payer from funding the true effectiveness of an innovation by expanding on their limitations. These include: 1) the normative nature of comparisons, 2) the impossibility of true effect imputability for each individual, and 3) the use of intermediary outcome measures. We then explore three main criticisms that payers must take into account when reasoning in terms of performance rather than in terms of the product effectiveness. Conclusion: The potential effect that performance-based reimbursements may have on dissociating the components of the cost-effectiveness ratio constitutes an obstacle to a true health economic reasoning. Keywords: risk sharing; pay for performance contract; comparative effectiveness research; cost-effectiveness studies (Published: 23 June 2014) Citation: Journal of Market Access & Health Policy 2014, 2: 24988 - http://dx.doi.org/10.3402/jmahp.v2.24988